Baseline CD4+/CD8+ TEMRA Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial.

J Blood Med · 2025 · PMC12515453 · PMID 41084724

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While primary outcomes did not reach statistical significance, survival benefits were observed, particularly in patients with severe (grade III–IV) disease who achieved an early treatment response.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Baseline CD4&lt;sup&gt;+&lt;/sup&gt;/CD8&lt;sup&gt;+&lt;/sup&gt; T&lt;sub&gt;EMRA&lt;/sub&gt; Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial.

The sentences

Baseline CD4<sup>+</sup>/CD8<sup>+</sup> T<sub>EMRA</sub> Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial.